Selective elimination of leukemia stem cells: Hitting a moving target

Cancer Letters

Volumn 338, Issue 1, 2013, Pages 15-22

  Crews, Leslie A ^a   Jamieson, Catriona H M ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

CML; Hematologic malignancies; Leukemia; Microenvironment; Stem cells; Therapeutics

Indexed keywords

BETA CATENIN; CD34 ANTIGEN; CD38 ANTIGEN; CHAPERONE; CYCLOPAMINE; DASATINIB; GDC 0049; IMATINIB; NILOTINIB; PF 04449913; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG; VISMODEGIB;

APOPTOSIS; BASAL CELL CARCINOMA; CANCER GROWTH; CANCER RESISTANCE; CANCER STEM CELL; CELL DIFFERENTIATION; CELL POPULATION; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EPIGENETICS; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA STEM CELL; MOLECULAR EVOLUTION; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT SURVEY; SIGNAL TRANSDUCTION; TARGET CELL; TUMOR MICROENVIRONMENT;

ERINACEIDAE;

EID: 84882913815     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.08.006     Document Type: Review

References (99)

1. Hamburger A.W., Salmon S.E. Primary bioassay of human tumor stem cells. Science 1977, 197:461-463.
2. Bomken S., Fiser K., Heidenreich O., Vormoor J. Understanding the cancer stem cell. Brit. J. Cancer 2010, 103:439-445.
3. Griffin J.D., Lowenberg B. Clonogenic cells in acute myeloblastic leukemia. Blood 1986, 68:1185-1195.
4. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3:730-737.
5. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., Minden M., Paterson B., Caligiuri M.A., Dick J.E. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
6. Blair A., Hogge D.E., Ailles L.E., Lansdorp P.M., Sutherland H.J. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood 1997, 89:3104-3112.
7. Darwin C. On the Origin of Species by Means of Natural Selection, or the Preservation of Favoured Races in the Struggle for Life 1859, John Murray, London.
8. Abrahamsson A.E., Geron I., Gotlib J., Dao K.H., Barroga C.F., Newton I.G., Giles F.J., Durocher J., Creusot R.S., Karimi M., Jones C., Zehnder J.L., Keating A., Negrin R.S., Weissman I.L., Jamieson C.H. Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc. Nat. Acad. Sci. USA 2009, 106:3925-3929.
9. Eppert K., Takenaka K., Lechman E.R., Waldron L., Nilsson B., Van Galen P., Metzeler K.H., Poeppl A., Ling V., Beyene J., Canty A.J., Danska J.S., Bohlander S.K., Buske C., Minden M.D., Golub T.R., Jurisica I., Ebert B.L., Dick J.E. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat. Med. 2011, 17:1086-1093.
10. - cells in acute myeloid leukemia. Blood 2012.
11. Fialkow P.J., Jacobson R.J., Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am. J. Med. 1977, 63:125-130.
12. Daley G.Q., Van Etten R.A., Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990, 247:824-830.
13. Jamieson C.H., Ailles L.E., Dylla S.J., Muijtjens M., Jones C., Zehnder J.L., Gotlib J., Li K., Manz M.G., Keating A., Sawyers C.L., Weissman I.L. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. Engl. J. Med. 2004, 351:657-667.
14. Krivtsov A.V., Twomey D., Feng Z., Stubbs M.C., Wang Y., Faber J., Levine J.E., Wang J., Hahn W.C., Gilliland D.G., Golub T.R., Armstrong S.A. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006, 442:818-822.
15. Wang Y., Krivtsov A.V., Sinha A.U., North T.E., Goessling W., Feng Z., Zon L.I., Armstrong S.A. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 2010, 327:1650-1653.
16. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Zimmermann J., Lydon N.B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 1996, 2:561-566.
17. Nowell P.C., Hungerford D.A. Chromosome studies on normal and leukemic human leukocytes. J. Nat. Cancer Inst. 1960, 25:85-109.
18. Rowley J.D. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. Nature 1973, 243:290-293.
19. Shtivelman E., Lifshitz B., Gale R.P., Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985, 315:550-554.
20. Ben-Neriah Y., Daley G.Q., Mes-Masson A.M., Witte O.N., Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 1986, 233:212-214.
21. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880.
22. Bhatia R., Holtz M., Niu N., Gray R., Snyder D.S., Sawyers C.L., Arber D.A., Slovak M.L., Forman S.J. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003, 101:4701-4707.
23. Mahon F.X., Rea D., Guilhot J., Guilhot F., Huguet F., Nicolini F., Legros L., Charbonnier A., Guerci A., Varet B., Etienne G., Reiffers J., Rousselot P. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop imatinib (STIM) trial. Lancet Oncol. 2010, 11:1029-1035.
24. Corbin A.S., Agarwal A., Loriaux M., Cortes J., Deininger M.W., Druker B.J. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J. Clin. Invest. 2011, 121:396-409.
25. Hamilton A., Helgason G.V., Schemionek M., Zhang B., Myssina S., Allan E.K., Nicolini F.E., Muller-Tidow C., Bhatia R., Brunton V.G., Koschmieder S., Holyoake T.L. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 2012, 119:1501-1510.
26. Nair R.R., Tolentino J., Hazlehurst L.A. The bone marrow microenvironment as a sanctuary for minimal residual disease in CML. Biochem. Pharmacol. 2010, 80:602-612.
27. Konopleva M.Y., Jordan C.T. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J. Clin. Oncol. 2011, 29:591-599.
28. Bellodi C., Lidonnici M.R., Hamilton A., Helgason G.V., Soliera A.R., Ronchetti M., Galavotti S., Young K.W., Selmi T., Yacobi R., Van Etten R.A., Donato N., Hunter A., Dinsdale D., Tirro E., Vigneri P., Nicotera P., Dyer M.J., Holyoake T., Salomoni P., Calabretta B. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J. Clin. Invest. 2009, 119:1109-1123.
29. Chen Y., Peng C., Sullivan C., Li D., Li S. Critical molecular pathways in cancer stem cells of chronic myeloid leukemia. Leukemia 2010, 24:1545-1554.
30. Rea D., Rousselot P., Guilhot J., Guilhot F., Mahon F.X. Curing chronic myeloid leukemia. Curr. Hematol. Malignancy Rep. 2012.
31. McGahon A., Bissonnette R., Schmitt M., Cotter K.M., Green D.R., Cotter T.G. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 1994, 83:1179-1187.
32. Dubrez L., Eymin B., Sordet O., Droin N., Turhan A.G., Solary E. BCR-ABL delays apoptosis upstream of procaspase-3 activation. Blood 1998, 91:2415-2422.
33. Amarante-Mendes G.P., Naekyung Kim C., Liu L., Huang Y., Perkins C.L., Green D.R., Bhalla K. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood 1998, 91:1700-1705.
34. Cambier N., Chopra R., Strasser A., Metcalf D., Elefanty A.G. BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner. Oncogene 1998, 16:335-348.
35. + progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. Leukemia 2005, 19:1034-1041.
36. Copland M., Hamilton A., Elrick L.J., Baird J.W., Allan E.K., Jordanides N., Barow M., Mountford J.C., Holyoake T.L. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006, 107:4532-4539.
37. Ng K.P., Hillmer A.M., Chuah C.T., Juan W.C., Ko T.K., Teo A.S., Ariyaratne P.N., Takahashi N., Sawada K., Fei Y., Soh S., Lee W.H., Huang J.W., Allen J.C., Woo X.Y., Nagarajan N., Kumar V., Thalamuthu A., Poh W.T., Ang A.L., Mya H.T., How G.F., Yang L.Y., Koh L.P., Chowbay B., Chang C.T., Nadarajan V.S., Chng W.J., Than H., Lim L.C., Goh Y.T., Zhang S., Poh D., Tan P., Seet J.E., Ang M.K., Chau N.M., Ng Q.S., Tan D.S., Soda M., Isobe K., Nothen M.M., Wong T.Y., Shahab A., Ruan X., Cacheux-Rataboul V., Sung W.K., Tan E.H., Yatabe Y., Mano H., Soo R.A., Chin T.M., Lim W.T., Ruan Y., Ong S.T. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat. Med. 2012, 18:521-528.
38. Kang M.H., Reynolds C.P. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin. Cancer Res. 2009, 15:1126-1132.
39. Ghobrial I.M., Witzig T.E., Adjei A.A. Targeting apoptosis pathways in cancer therapy. Cancer J. Clin. 2005, 55:178-194.
40. Mak D.H., Wang R.Y., Schober W.D., Konopleva M., Cortes J., Kantarjian H., Andreeff M., Carter B.Z. Activation of apoptosis signaling eliminates CD34(+) progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors. Leukemia 2012, 26:788-794.
41. Airiau K., Mahon F.X., Josselin M., Jeanneteau M., Turcq B., Belloc F. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib. Exp. Hematol. 2012.
42. Aichberger K.J., Mayerhofer M., Krauth M.T., Skvara H., Florian S., Sonneck K., Akgul C., Derdak S., Pickl W.F., Wacheck V., Selzer E., Monia B.P., Moriggl R., Valent P., Sillaber C. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 2005, 105:3303-3311.
43. Chien A.J., Conrad W.H., Moon R.T. A Wnt survival guide: from flies to human disease. J. Invest. Dermatol. 2009, 129:1614-1627.
44. Reya T., Clevers H. Wnt signalling in stem cells and cancer. Nature 2005, 434:843-850.
45. Radich J.P., Dai H., Mao M., Oehler V., Schelter J., Druker B., Sawyers C., Shah N., Stock W., Willman C.L., Friend S., Linsley P.S. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc. Nat. Acad. Sci. USA 2006, 103:2794-2799.
46. Zhao C., Blum J., Chen A., Kwon H.Y., Jung S.H., Cook J.M., Lagoo A., Reya T. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 2007, 12:528-541.
47. Minami Y., Stuart S.A., Ikawa T., Jiang Y., Banno A., Hunton I.C., Young D.J., Naoe T., Murre C., Jamieson C.H., Wang J.Y. BCR-ABL-transformed GMP as myeloid leukemic stem cells. Proc. Nat. Acad. Sci. USA 2008, 105:17967-17972.
48. Coluccia A.M., Vacca A., Dunach M., Mologni L., Redaelli S., Bustos V.H., Benati D., Pinna L.A., Gambacorti-Passerini C. Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J 2007, 26:1456-1466.
49. Nagao R., Ashihara E., Kimura S., Strovel J.W., Yao H., Takeuchi M., Tanaka R., Hayashi Y., Hirai H., Padia J., Strand K., Maekawa T. Growth inhibition of imatinib-resistant CML cells with the T315I mutation and hypoxia-adaptation by AV65 - a novel Wnt/beta-catenin signaling inhibitor. Cancer Lett. 2011, 312:91-100.
50. Heidel F.H., Bullinger L., Feng Z., Wang Z., Neff T.A., Stein L., Kalaitzidis D., Lane S.W., Armstrong S.A. Genetic and pharmacological inhibition of beta-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell 2012, 10:412-424.
51. Perrotti D., Jamieson C., Goldman J., Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. J. Clin. Invest. 2010, 120:2254-2264.
52. Riobo N.A., Lu K., Ai X., Haines G.M., Emerson C.P. Phosphoinositide 3-kinase and Akt are essential for Sonic hedgehog signaling. Proc. Nat. Acad. Sci. USA 2006, 103:4505-4510.
53. Bhardwaj G., Murdoch B., Wu D., Baker D.P., Williams K.P., Chadwick K., Ling L.E., Karanu F.N., Bhatia M. Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation. Nat. Immunol. 2001, 2:172-180.
54. Gering M., Patient R. Hedgehog signaling is required for adult blood stem cell formation in zebrafish embryos. Dev. Cell 2005, 8:389-400.
55. Trowbridge J.J., Scott M.P., Bhatia M. Hedgehog modulates cell cycle regulators in stem cells to control hematopoietic regeneration. Proc. Nat. Acad. Sci. USA 2006, 103:14134-14139.
56. Machold R., Hayashi S., Rutlin M., Muzumdar M.D., Nery S., Corbin J.G., Gritli-Linde A., Dellovade T., Porter J.A., Rubin L.L., Dudek H., McMahon A.P., Fishell G. Sonic hedgehog is required for progenitor cell maintenance in telencephalic stem cell niches. Neuron 2003, 39:937-950.
57. Chiang C., Swan R.Z., Grachtchouk M., Bolinger M., Litingtung Y., Robertson E.K., Cooper M.K., Gaffield W., Westphal H., Beachy P.A., Dlugosz A.A. Essential role for Sonic hedgehog during hair follicle morphogenesis. Dev. Biol. 1999, 205:1-9.
58. Dierks C., Beigi R., Guo G.R., Zirlik K., Stegert M.R., Manley P., Trussell C., Schmitt-Graeff A., Landwerlin K., Veelken H., Warmuth M. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 2008, 14:238-249.
59. Zhao C., Chen A., Jamieson C.H., Fereshteh M., Abrahamsson A., Blum J., Kwon H.Y., Kim J., Chute J.P., Rizzieri D., Munchhof M., VanArsdale T., Beachy P.A., Reya T. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009, 458:776-779.
60. Cooper M.K., Porter J.A., Young K.E., Beachy P.A. Teratogen-mediated inhibition of target tissue response to Shh signaling. Science 1998, 280:1603-1607.
61. Incardona J.P., Gaffield W., Kapur R.P., Roelink H. The teratogenic Veratrum alkaloid cyclopamine inhibits sonic hedgehog signal transduction. Development 1998, 125:3553-3562.
62. Chiang C., Litingtung Y., Lee E., Young K.E., Corden J.L., Westphal H., Beachy P.A. Cyclopia and defective axial patterning in mice lacking Sonic hedgehog gene function. Nature 1996, 383:407-413.
63. Roessler E., Belloni E., Gaudenz K., Jay P., Berta P., Scherer S.W., Tsui L.C., Muenke M. Mutations in the human Sonic Hedgehog gene cause holoprosencephaly. Nat. Genet. 1996, 14:357-360.
64. Belloni E., Muenke M., Roessler E., Traverso G., Siegel-Bartelt J., Frumkin A., Mitchell H.F., Donis-Keller H., Helms C., Hing A.V., Heng H.H., Koop B., Martindale D., Rommens J.M., Tsui L.C., Scherer S.W. Identification of Sonic hedgehog as a candidate gene responsible for holoprosencephaly. Nat. Genet. 1996, 14:353-356.
65. Scales S.J., De Sauvage F.J. Mechanisms of hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol. Sci. 2009, 30:303-312.
66. Rudin C.M., Hann C.L., Laterra J., Yauch R.L., Callahan C.A., Fu L., Holcomb T., Stinson J., Gould S.E., Coleman B., LoRusso P.M., Von Hoff D.D., de Sauvage F.J., Low J.A. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. Engl. J. Med. 2009, 361:1173-1178.
67. Von Hoff D.D., LoRusso P.M., Rudin C.M., Reddy J.C., Yauch R.L., Tibes R., Weiss G.J., Borad M.J., Hann C.L., Brahmer J.R., Mackey H.M., Lum B.L., Darbonne W.C., Marsters J.C., De Sauvage F.J., Low J.A. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. Engl. J. Med. 2009, 361:1164-1172.
68. Metcalfe C., De Sauvage F.J. Hedgehog fights back: mechanisms of acquired resistance against smoothened antagonists. Cancer Res. 2011, 71:5057-5061.
69. Marks P.A., Richon V.M., Miller T., Kelly W.K. Histone deacetylase inhibitors. Adv. Cancer Res. 2004, 91:137-168.
70. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 2006, 5:769-784.
71. Burgess A., Ruefli A., Beamish H., Warrener R., Saunders N., Johnstone R., Gabrielli B. Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene 2004, 23:6693-6701.
72. Fiskus W., Pranpat M., Bali P., Balasis M., Kumaraswamy S., Boyapalle S., Rocha K., Wu J., Giles F., Manley P.W., Atadja P., Bhalla K. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood 2006, 108:645-652.
73. Fiskus W., Pranpat M., Balasis M., Bali P., Estrella V., Kumaraswamy S., Rao R., Rocha K., Herger B., Lee F., Richon V., Bhalla K. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin. Cancer Res. 2006, 12:5869-5878.
74. Nimmanapalli R., Fuino L., Bali P., Gasparetto M., Glozak M., Tao J., Moscinski L., Smith C., Wu J., Jove R., Atadja P., Bhalla K. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res. 2003, 63:5126-5135.
75. Nimmanapalli R., Fuino L., Stobaugh C., Richon V., Bhalla K. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 2003, 101:3236-3239.
76. Zhang B., Strauss A.C., Chu S., Li M., Ho Y., Shiang K.D., Snyder D.S., Huettner C.S., Shultz L., Holyoake T., Bhatia R. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 2010, 17:427-442.
77. Li L., Wang L., Li L., Wang Z., Ho Y., McDonald T., Holyoake T.L., Chen W., Bhatia R. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 2012, 21:266-281.
78. Chen Y., Hu Y., Zhang H., Peng C., Li S. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat. Genet. 2009, 41:783-792.
79. Tauchi T., Okabe S., Ashihara E., Kimura S., Maekawa T., Ohyashiki K. Combined effects of novel heat shock protein 90 inhibitor NVP-AUY922 and nilotinib in a random mutagenesis screen. Oncogene 2011, 30:2789-2797.
80. Apperley J.F. Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007, 8:1018-1029.
81. Holyoake T., Jiang X., Eaves C., Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 1999, 94:2056-2064.
82. Ishikawa F., Yoshida S., Saito Y., Hijikata A., Kitamura H., Tanaka S., Nakamura R., Tanaka T., Tomiyama H., Saito N., Fukata M., Miyamoto T., Lyons B., Ohshima K., Uchida N., Taniguchi S., Ohara O., Akashi K., Harada M., Shultz L.D. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat. Biotechnol. 2007, 25:1315-1321.
83. Chu S., McDonald T., Lin A., Chakraborty S., Huang Q., Snyder D.S., Bhatia R. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood 2011, 118:5565-5572.
84. Graham S.M., Jorgensen H.G., Allan E., Pearson C., Alcorn M.J., Richmond L., Holyoake T.L. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002, 99:319-325.
85. Konopleva M., Konoplev S., Hu W., Zaritskey A.Y., Afanasiev B.V., Andreeff M. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia 2002, 16:1713-1724.
86. Reynaud D., Pietras E., Barry-Holson K., Mir A., Binnewies M., Jeanne M., Sala-Torra O., Radich J.P., Passegue E. IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell 2011, 20:661-673.
87. Jamieson C.H., Barroga C.F., Vainchenker W.P. Miscreant myeloproliferative disorder stem cells. Leukemia 2008, 22:2011-2019.
88. Jin L., Tabe Y., Konoplev S., Xu Y., Leysath C.E., Lu H., Kimura S., Ohsaka A., Rios M.B., Calvert L., Kantarjian H., Andreeff M., Konopleva M. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol. Cancer Therap. 2008, 7:48-58.
89. Todaro M., Alea M.P., Di Stefano A.B., Cammareri P., Vermeulen L., Iovino F., Tripodo C., Russo A., Gulotta G., Medema J.P., Stassi G. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007, 1:389-402.
90. Nishimura E.K., Suzuki M., Igras V., Du J., Lonning S., Miyachi Y., Roes J., Beermann F., Fisher D.E. Key roles for transforming growth factor beta in melanocyte stem cell maintenance. Cell Stem Cell 2010, 6:130-140.
91. Calabrese C., Poppleton H., Kocak M., Hogg T.L., Fuller C., Hamner B., Oh E.Y., Gaber M.W., Finklestein D., Allen M., Frank A., Bayazitov I.T., Zakharenko S.S., Gajjar A., Davidoff A., Gilbertson R.J. A perivascular niche for brain tumor stem cells. Cancer Cell 2007, 11:69-82.
92. Gilbert L.A., Hemann M.T. DNA damage-mediated induction of a chemoresistant niche. Cell 2010, 143:355-366.
93. Saito Y., Uchida N., Tanaka S., Suzuki N., Tomizawa-Murasawa M., Sone A., Najima Y., Takagi S., Aoki Y., Wake A., Taniguchi S., Shultz L.D., Ishikawa F. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat. Biotechnol. 2010, 28:275-280.
94. Jin L., Hope K.J., Zhai Q., Smadja-Joffe F., Dick J.E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 2006, 12:1167-1174.
95. Krause D.S., Lazarides K., von Andrian U.H., Van Etten R.A. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat. Med. 2006, 12:1175-1180.
96. Nie Y., Han Y.C., Zou Y.R. CXCR4 is required for the quiescence of primitive hematopoietic cells. J. Exp. Med. 2008, 205:777-783.
97. Sugiyama T., Kohara H., Noda M., Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006, 25:977-988.
98. Weisberg E., Azab A.K., Manley P.W., Kung A.L., Christie A.L., Bronson R., Ghobrial I.M., Griffin J.D. Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib. Leukemia 2011.
99. O'Callaghan K., Lee L., Nguyen N., Hsieh M.Y., Kaneider N.C., Klein A.K., Sprague K., Van Etten R.A., Kuliopulos A., Covic L. Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia. Blood 2012, 119:1717-1725.